Professor | Zhan Zhengsheng | Asia Growth Partners

Name	Zhan Zhengsheng
Contact Information	zszhan@simm.ac.cn
Language ability	Chinese, English
Province	Shanghai

Name

Zhan Zhengsheng

Contact Information

zszhan@simm.ac.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	University of Chinese Academy of Sciences
Faculty	Medical School
Academic Background & Achievements	2008-09 to 2014-06 PhD: University of Chinese Academy of Sciences 2004-09 to 2008-06 Bachelor's: China Pharmaceutical University
Work Experience	2021-10 to Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher 2016-10 to 2021-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher 2016-08 to 2016-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Assistant Researcher 2014-07 to 2016-08 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Postdoctoral Researcher 2008-09 to 2014-06 - University of Chinese Academy of Sciences - PhD Student 2004-09 to 2008-06 - China Pharmaceutical University - Bachelor's Student
Awards	Shanghai Science and Technology Commission 'Sailing Program' (2020): Provincial Level Member of the Youth Innovation Promotion Association of the Chinese Academy of Sciences (2018): Ministerial Level Outstanding Employee of Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2018): Institute Level

University/Lab Affiliation and Title

University of Chinese Academy of Sciences

Faculty

Medical School

Academic Background & Achievements

2008-09 to 2014-06 PhD: University of Chinese Academy of Sciences
2004-09 to 2008-06 Bachelor's: China Pharmaceutical University

Work Experience

2021-10 to Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher
2016-10 to 2021-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
2016-08 to 2016-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Assistant Researcher
2014-07 to 2016-08 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Postdoctoral Researcher
2008-09 to 2014-06 - University of Chinese Academy of Sciences - PhD Student
2004-09 to 2008-06 - China Pharmaceutical University - Bachelor's Student

Awards

Shanghai Science and Technology Commission 'Sailing Program' (2020): Provincial Level
Member of the Youth Innovation Promotion Association of the Chinese Academy of Sciences (2018): Ministerial Level
Outstanding Employee of Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2018): Institute Level

Areas of Focus	Discovery of STING inhibitors for the treatment of autoimmune and inflammatory diseases
Publications	Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma, Acta Pharmaceutica Sinica B, 2023 Design, synthesis, and STING-agonistic activity of benzo[b]thiophene-2-carboxamide derivatives, Molecular Diversity, 2023 Discovery of 10H-Benzobpyrido2,3-e1,4oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase, Journal of Medicinal Chemistry, 2022 Synthesis of triazolotriazine derivatives as c-Met inhibitors, Molecular Diversity, 2021 Evaluation of deuterium-labeled JNJ38877605: pharmacokinetic, metabolic, and in vivo antitumor profiles, Chemical Research in Toxicology, 2018 Discovery of 6-(difluoro(6-(4-fluorophenyl)-1,2,4triazolo4,3-b1,2,4triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor, European Journal of Medicinal Chemistry, 2016 Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities, Oncotarget, 2016 Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity, ACS Medicinal Chemistry Letters, 2014

Areas of Focus

Discovery of STING inhibitors for the treatment of autoimmune and inflammatory diseases

Publications

Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma, Acta Pharmaceutica Sinica B, 2023
Design, synthesis, and STING-agonistic activity of benzo[b]thiophene-2-carboxamide derivatives, Molecular Diversity, 2023
Discovery of 10H-Benzobpyrido2,3-e1,4oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase, Journal of Medicinal Chemistry, 2022
Synthesis of triazolotriazine derivatives as c-Met inhibitors, Molecular Diversity, 2021
Evaluation of deuterium-labeled JNJ38877605: pharmacokinetic, metabolic, and in vivo antitumor profiles, Chemical Research in Toxicology, 2018
Discovery of 6-(difluoro(6-(4-fluorophenyl)-1,2,4triazolo4,3-b1,2,4triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor, European Journal of Medicinal Chemistry, 2016
Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities, Oncotarget, 2016
Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity, ACS Medicinal Chemistry Letters, 2014

Sting Inhibitors Autoimmune Diseases Inflammatory Diseases Drug Discovery Pharmacology Immunology Biochemistry Molecular Biology Therapeutics Medicinal Chemistry

Shijun He - University of Chinese Academy of Sciences

Qian Youcun - University of Chinese Academy of Sciences

Jianping Zuo - University of Chinese Academy of Sciences

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us